alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 75, Number 42 (Thursday, March 4, 2010)]
[Notices]
[Page 9912]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4492]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Sickle Cell Disease Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Sickle Cell Disease Advisory Committee.
    Date: March 26, 2010.
    Time: 8:30 a.m. to 4:30 p.m.
    Agenda: Discussion of Programs and Issues.
    Place: National Institutes of Health, 6701 Rockledge Drive, 10th 
Floor, Conference Room 10091, Bethesda, MD 20892.
    Contact Person: W. Keith Hoots, Director, Division of Blood 
Diseases and Resources, National Heart, Lung, and Blood Institute, 
6701 Rockledge Drive, Suite 9030, Bethesda, MD 20892, 301-435-0080, 
<a href="/cdn-cgi/l/email-protection#51393e3e2522263a113f393d33387f3f38397f363e27"><span class="__cf_email__" data-cfemail="84ecebebf0f7f3efc4eaece8e6edaaeaedecaae3ebf2">[email protected]</span></a>.

    Information is also available on the Institute's/Center's home 
page: http:/www.nhlbi.nih.gov/meetings/index.htm, where an agenda 
and any additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: February 23, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4492 Filed 3-3-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit
      32




**Certification
      of Periodic Financial Report**


**Pursuant
      to Rule 13a- 14(a)/15d-14(a)**




Pursuant
      to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002, each of the undersigned officers of AMCOL
      International Corporation (the “Company”) certifies that the quarterly report on
      Form 10-Q of the Company for the three months ended June 30, 2007 fully complies
      with the requirements of Section 13(a) or 15(d) of the Securities Exchange
      Act
      of 1934 and information contained in that Form 10-Q fairly presents, in all
      material respects, the financial condition and results of operations of the
      Company.








Date: 
                August 9, 2007
            /s/
                Lawrence E. WashowLawrence
                E. Washow
              Chief
                Executive OfficerDate: 
                August 9, 2007
            /s/
                Gary L. CastagnaGary
                L. Castagna
              Chief
                Financial Officer
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.6100 Anesthetic cabinet, table, or tray. ( a ) *Identification.* An anesthetic cabinet, table, or tray is a device intended to store anesthetic equipment and drugs. The device is usually constructed to eliminate build-up of static electrical charges.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 54 FR 25048, June 12, 1989; 66 FR 38796, July 25, 2001]
| (logo) WELLS FARGO | CMBS Department

 

MAC N9401-011

1055 10th Avenue SE

Minneapolis, MN 55414 |
|--------------------|------------------------------------------------------------------------------------|

 

Morgan Stanley Capital I Inc.

1585 Broadway

New York, New York 10036

 

 

RE: Annual Statement of Compliance for Morgan Stanley Bank of America Merrill Lynch Trust 2015-C23, Commercial Mortgage Pass-Through Certificates Series 2015-C23

 

Per the Pooling and Servicing Agreement dated as of June 1, 2015 (the "Agreement"), the undersigned, a duly authorized officer of Wells Fargo Bank, N.A., as Custodian ("Wells Fargo"), hereby certifies as follows as of and for the year ending December 31, 2015 (the "Reporting Period"):

 

(a) A review of Wells Fargo's activities during the Reporting Period and of its performance under the Agreement has been made under such officer's supervision; and

 

(b) To the best of such officer's knowledge, based on such review, Wells Fargo has fulfilled all of its obligations under the Agreement in all material respects throughout the Reporting Period.

 

 

March 1, 2016

/s/ Gail Vannest

GAIL VANNEST

Vice President

 

 

Wells Fargo Bank, N.A.
Exhibit 24

                                POWER OF ATTORNEY

      Each Director of PSEG Energy Holdings Inc. whose  signature  appears below
hereby  appoints  Bruce  E.  Walenczyk  the  agent  for  service  named  in this
Registration Statement, and James T. Foran, Esq. as attorney-in-fact, to execute
in the name of each such  person and to file with the  Securities  and  Exchange
Commission this  Registration  Statement and any and all additional  amendments,
including post-effective amendments to this Registration Statement.

          Signature                      Title                      Date
          ---------                      -----                      ----

      /s/ FRANK CASSIDY                 Director               July 10, 2000
----------------------------
        Frank Cassidy

/s/ ROBERT J. DOUGHERTY, JR.            Director               July 10, 2000
----------------------------
     Robert J. Dougherty

    /s/ E. JAMES FERLAND                Director               July 10, 2000
----------------------------
      E. James Ferland

    /s/ ROBERT C. MURRAY                Director               July 10, 2000
----------------------------
      Robert C. Murray

    /s/ R. EDWIN SELOVER                Director               July 10, 2000
----------------------------
      R. Edwin Selover
#### § 1303.26 Reduction in individual manufacturing quotas.

The Administrator may at any time reduce an individual manufacturing quota for a basic class of controlled substance listed in Schedule I or II which he has previously fixed in order to prevent the aggregate of the individual manufacturing quotas and import permits outstanding or to be granted from exceeding the aggregate production quota which has been established for that class pursuant of § 1303.11, as adjusted pursuant to § 1303.13. If a quota assigned to a new manufacturer pursuant to § 1303.23(b), or if a quota assigned to any manufacturer is increased pursuant to § 1303.24(c), or if an import permit issued to an importer pursuant to part 1312 of this chapter, causes the total quantity of a basic class to be manufactured and imported during the year to exceed the aggregate production quota which has been established for that class pursuant to § 1303.11, as adjusted pursuant to § 1303.13, the Administrator may proportionately reduce the individual manufacturing quotas and import permits of all other registrants to keep the aggregate production quota within the limits originally established, or, alternatively, the Administrator may reduce the individual manufacturing quota of any registrant whose quota is suspended pursuant to § 1303.24(b) or § 1301.36 of this chapter, or is abandoned pursuant to § 1303.27.

[36 FR 7786, Apr. 24, 1971, as amended at 37 FR 15920, Aug. 8, 1972. Redesignated at 38 FR 26609, Sept. 24, 1973, as amended at 62 FR 13958, Mar. 24, 1997]
§ 573.200 Condensed animal protein hydrolysate. ( a ) *Identity.* The condensed animal protein hydrolysate is produced from the meat byproducts scraped from cured (salted) hides taken from cattle slaughtered for food consumption. The meat byproduct is hydrolyzed with heat and phosphoric acid.
( b ) *Specifications.* The additive shall conform to the following percent-by-weight specifications: Moisture, not less than 45 percent nor more than 50 percent. Protein, not less than 24 percent. Salt (NaCl), not more than 15 percent. Phosphorus, not less than 2.25 percent.
( c ) *Uses.* It is used or intended for use as a source of animal protein, phosphorus, and salt (NaCl) as follows: ( 1 ) In poultry and swine feed in an amount not to exceed 5 percent by weight of the feed.
( 2 ) In feed concentrates for cattle in an amount not to exceed 10 percent by weight of the concentrate.
( d ) *Labeling.* The label and labeling shall bear, in addition to the other information required by the act: ( 1 ) The name of the additive, condensed animal protein hydrolysate.
( 2 ) Adequate directions for use including maximum quantities permitted for each species and a guaranteed analysis of the additive.
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5590 Lipoprotein X immunological test system. ( a ) *Identification.* A lipoprotein X immunological test system is a device that consists of the reagents used to measure by immunochemical techniques lipoprotein X (a high-density lipoprotein) in serum and other body fluids. Measurement of lipoprotein X aids in the diagnosis of obstructive liver disease.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 65 FR 2313, Jan. 14, 2000]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5860 Pressure tubing and accessories. ( a ) *Identification.* Pressure tubing and accessories are flexible or rigid devices intended to deliver pressurized medical gases.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38796, July 25, 2001]
§ 74.2101 FD&C Blue No. 1. ( a ) *Identity.* The color additive FD&C Blue No. 1 is principally the disodium salt of ethyl[4-[*p*-[ethyl(*m*-sulfobenzyl)amino]-α-(*o*-sulfophenyl)benzylidene]-2,5-cyclohexadien-1-ylidene](*m*-sulfobenzyl)ammonium hydroxide inner salt with smaller amounts of the isomeric disodium salts of ethyl[4-[*p*-[ethyl(*p*-sulfobenzyl)amino]-α-(*o*-sulfophenyl)benzylidene]-2,5-cyclohexadien-1-ylidene](*p*-sulfobenzyl)ammonium hydroxide inner salt and ethyl[4-[*p*-[ethyl(*o*-sulfobenzyl)amino]-α-(*o*-sulfophenyl)benzylidene]-2,5-cyclohexadien-1-ylidene](*o*-sulfobenzyl)ammonium hydroxide inner salt. Additionally, FD&C Blue No. 1 is manufactured by the acid catalyzed condensation of one mole of sodium 2-formylbenzenesulfonate with two moles from a mixture consisting principally of 3-[(ethylphenylamino)methyl] benzenesulfonic acid, and smaller amounts of 4-[(ethylphenylamino)methyl] benzenesulfonic acid and 2-[(ethylphenylamino)methyl] benzenesulfonic acid to form the leuco base. The leuco base is then oxidized with lead dioxide and acid, or with dichromate and acid, or with manganese dioxide and acid to form the dye. The intermediate sodium 2-formylbenzenesulfonate is prepared from 2-chlorobenzaldehyde and sodium sulfite.
( b ) *Specifications.* ( 1 ) The color additive FD&C Blue No. 1 shall conform in specifications to the requirements of § 74.101(b).
( 2 ) FD&C Blue No. 1 Aluminum Lake shall be prepared in accordance with the requirements of § 82.51 of this chapter.
( c ) *Uses and restrictions.* ( 1 ) FD&C Blue No. 1 may be safely used for coloring cosmetics generally, including cosmetics intended for use in the area of the eye, in amounts consistent with current good manufacturing practice.
( 2 ) FD&C Blue No. 1 Aluminum Lake may be safely used for coloring cosmetics intended for use in the area of the eye, in amounts consistent with current good manufacturing practice.
( d ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of FD&C Blue No. 1 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 42565, Sept. 28, 1982, as amended at 58 FR 17511, Apr. 5, 1993; 59 FR 7638, Feb. 16, 1994]
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.1298 Ferric ammonium ferrocyanide. ( a ) *Identity.* ( 1 ) The color additive ferric ammonium ferrocyanide is the blue pigment obtained by oxidizing under acidic conditions with sodium dichromate the acid digested precipitate resulting from mixing solutions of ferrous sulfate and sodium ferrocyanide in the presence of ammonium sulfate. The oxidized product is filtered, washed, and dried. The pigment consists principally of ferric ammonium ferrocyanide with smaller amounts of ferric ferrocyanide and ferric sodium ferrocyanide.
( 2 ) Color additive mixtures for drug use made with ferric ammonium ferrocyanide may contain only those diluents listed in this subpart as safe and suitable for use in color additive mixtures for coloring drugs.
( b ) *Specifications.* Ferric ammonium ferrocyanide shall conform to the following specifications and shall be free of impurities other than those named to the extent that the other impurities may be avoided by good manufacturing practice: Oxalic acid or its salts, not more than 0.1 percent. Water soluble matter, not more than 3 percent. Water soluble cyanide, not more than 10 parts per million. Volatile matter, not more than 4 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Nickel (as Ni), not more than 200 parts per million. Cobalt (as Co), not more than 200 parts per million. Mercury (as Hg), not more than 1 part per million. Total iron (as Fe corrected for volatile matter), not less than 33 percent and not more than 39 percent.
( c ) *Uses and restrictions.* Ferric ammonium ferrocyanide may be safely used in amounts consistent with good manufacturing practice to color externally applied drugs, including those for use in the area of the eye.
( d ) *Labeling requirements.* The label of the color additive and of any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therfore batches thereof are exempt from the certification requirements of section 721(c) of the act.
[42 FR 38562, July 29, 1977, as amended at 44 FR 28322, May 15, 1979]
11TH COURT OF APPEALS

EASTLAND, TEXAS

JUDGMENT

Saul Pena, * From the 70th District Court

of Ector County,

Trial Court No. A-18-1605-CR.

Vs. No. 11-23-00255-CR * July 18, 2024

The State of Texas, * Memorandum Opinion by Trotter, J.

(Panel consists of: Bailey, C.J.,

Trotter, J., and Williams, J.)

This court has inspected the record in this cause and concludes that there is no 

error in the judgment below. Therefore, in accordance with this court’s opinion, 

the judgment of the trial court is in all things affirmed.
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.1085 Caramel. ( a ) *Identity and specifications.* ( 1 ) The color additive caramel shall conform in identity and specifications to the requirements of § 73.85(a) (1), (2), and (3) and (b).
( 2 ) The diluents in color additive mixtures for drug use containing caramel shall be limited to those listed in this subpart as safe and suitable in color additive mixtures for coloring drugs.
( b ) *Uses and restrictions.* Caramel may be used for coloring ingested and topically applied drugs generally in amounts consistent with good manufacturing practice.
( c ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health and therefore batches thereof are exempt from the certification requirement of section 721(c) of the act.
## NO. 12

- 10

- 00 01 6

- CR

IN THE COURT OF APPEALS

TWELFTH COURT OF APPEALS DISTRICT

TYLER, TEXAS

QUILLON AKMON BROWN

, § APPEAL FROM THE 7TH

APPELLANT

V. § JUDICIAL DISTRICT COURT

THE STATE OF TEXAS,

APPELLEE § SMITH COUNT Y, TEXAS

MEMORANDUM OPINION

PER CURIAM

Appellant has filed a motion to dismiss this appeal. The motion is signed by Appellant and

by his counsel. No decision having been delivered by this court, the motion is granted, and the

appeal is dismissed in a ccordance with Texas Rule of Appellate Procedure 42.2.

Opinion delivered May 19 , 20 10

. Panel consisted of Worthen, C.J., Griffith, J., and Hoyle, J.

(DO NOT PUBLISH)
#### Cadwell *v.*Swift & Company.

No. 8304.

February 10, 1932.

*William B. Kent,*for plaintiff.

*Kirlcland &*Ilirlcland, for defendants.

Atkinson, J.

1. A power of sale in a deed of trust, mortgage, or other

instrument is to be strictly construed and must be fairly exercised. In the absence of stipulations to the contrary in the instrument, the time, place, and manner of the sale should be that pointed out for public sales. Civil Code, § 4620. However, “that portion of the mortgage containing the power, like all other contracts, is to be construed so as to effectuate the intention of the parties, and the power must be exercised in accordance with the intention of the parties as indicated in the clause in the mortgage conferring the power.” *Garrett*v. *Crawford,*128 *Ga.*519-521 (57 S. E. 792, 119 Am. St. R. 398, 11 Ann. Cas. 167) ; *Mathis*v. *Glawson,*149 *Ga.*752 (3) (102 S. E. 351). Accordingly, where land located in Treutlen County is conveyed by deed as security for debt, and the deed contains a power of sale authorizing sale of the land in Candler County for collection of the debt, the sale in virtue of the contract should be held in Candler County.

2. Equity eases shall be tried in the county where a defendant resides against whom substantial relief is prayed. Civil Code, § 6540. A corporation of this State is not subject to a suit for equitable relief by injunction in a county other than that fixed by its charter as the county of its principal office. *Etowah Milling Co.*v. *Crenshaw,*116 *Ga.*406 (42 S. E. 709); *Porter*v. *State Mutual Life Insurance Co.,*145 *Ga.*543 (89 S. E. 609); *Georgia Land &c. Co.*v. *Savannah River Lumber Co.,*150 *Ga.*202 (103 S. E. 167). Accordingly, where a suit to enjoin exercise of a power of sale contained in a security deed is instituted in Treutlen County solely against a commercial corporation of this State, the principal office of which as fixed by its charter is in another county, the court is without jurisdiction.

3. Under the pleadings and the evidence, the action was improperly instituted in Treutlen County, and the judge did not err in refusing a temporary injunction. *Judgment affirmed.*

*All the Justices concur.*
<PAGE>   1

                                                                    EXHIBIT 23.1

                       CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the use in this Registration Statement on Form S-1 of our
report dated March 17, 1999, except as to the third through sixth paragraphs of
Note 12, which are as of May 11, 1999, and except as to the seventh paragraph of
Note 12 which is as of May 14, 1999, relating to the financial statements of
N2H2, Inc. which appears in such Registration Statement. We also consent to the
references to us under the headings "Experts" and "Selected Financial Data" in
such Prospectus. However, it should be noted that PricewaterhouseCoopers LLP has
not prepared or certified such "Selected Financial Data" in such Registration
Statement.

PricewaterhouseCoopers LLP
Seattle, Washington

July 7, 1999
Gila River Indian Community 

Department of Environmental Qualily 

Air Program 

P.O. Box 97 - Sacaton, Az. - 85247 

Phone: (520) 562-2234 Fax: (520) 562-2245 

EM TR.1NSMlSSlON 

TO: &d-f;cf 5 %vice 

Aan: $~vv~h %~wfld( 

Fax: 5coa--*35 

Front: 5- ~ivi s 

Date: 5 -27 -05 

J 

Pages (including this page): a, 

cc: 

COMMENTS: 
GILA RIVER INDIAN COMMUNlTY 

DEPARTMENT OF ENVIRONMENTAL QUALITY 

AIR PROGRAM 

MEMO 

DATE: May 27,2005 

TO: Ms. Sarah Burnell 

FROM: Janet Travis, Environmental Project 

RE. Elderly Concerns Meeting 

The GRIC Department of Environmental Quality is re uesting placement on the agenda $ for the upcoming Elderly Concerns meeting on June 8 ,2005. The air program would 

like to present information on proposed ordinances that will regulate sources of air 

pollution within the Community. We are particularly interested in comments on open 

burning. 

Please call me at 520-562-2234 ext. 286 if you have any questions 
1 

I 

TRANSMISSION VERIFICATION REPORT I 

TIME : 05/27/2005 14: 51 

NAME : DEPT DEQ 

FAX : 5205622245 

TEL : 5205622234 

Gila River jndian Community 

Department of Emiromental Quality 

Air Program 

P.O. Box 97 - Sacaton, Az. - 85247 

Phone: (520) 562-2234 Fax: (520) 562-2245 

-.- . - 

FAX TR4NSMISSSION 

From: gw ~mvj s 

Date: CJ -77-05 

Re: e( &I &cx4Wfl5 ~5 . Y 

Pages (incluoYng this page): 2 

CC.'
EXHIBIT 32.1

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Avitar, Inc. (the "Company") on
Form10-QSB for the period ending June 30, 2005 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Peter P. Phildius,
Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to
my knowledge, that:

     (1) The Report fully complies with the requirements of Section 13(a)
or15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Date: August 15, 2005

                                               /s/ Peter P. Phildius
                                               ---------------------
                                               Peter P. Phildius Chief
                                               Executive Officer